### FORM NO. MGT-7

[Pursuant to sub-Section(1) of section 92 of the Companies Act, 2013 and sub-rule (1) of rule 11of the Companies (Management and Administration) Rules, 2014]

(vi) \*Whether shares listed on recognized Stock Exchange(s)



### **Annual Return**

(other than OPCs and Small Companies)

I. RI	EGISTRATION AND OTHE	R DETAILS			
(i) * C	Corporate Identification Number (0	CIN) of the company	U74999T	G2000PTC035826	Pre-fill
C	Global Location Number (GLN) of	the company			
* F	Permanent Account Number (PAN	N) of the company	AABCG3	208J	
ii) (a	) Name of the company		ARAGEN	LIFE SCIENCES PRIVAT	
(b	) Registered office address				
	Plot 28A, IDA Nacharam, Hyderabad Telangana 500076		compliar	nces@aragen.com	
(c	l) *Telephone number with STD c	ode	0406692		
(€	e) Website				
iii)	Date of Incorporation		07/12/20	000	
v)	Type of the Company	Category of the Company		Sub-category of the C	Company
	Private Company Company limited by sha		nares Indian Non-Go		rnment company

Yes

No

(vii) *Financial year From date 01/0	04/2021	(DD/MM/YYYY)	To date	31/03/2022	(DD/MM/YYYY)		
(viii) *Whether Annual general mee	ing (AGM) held	<ul><li>Ye</li></ul>	es 🔾	No			
(a) If yes, date of AGM	24/08/2022						
(b) Due date of AGM	30/09/2022						
(c) Whether any extension for	AGM granted	$\circ$	) Yes	<ul><li>No</li></ul>			
II. PRINCIPAL BUSINESS ACTIVITIES OF THE COMPANY							
*Number of business activitie	es 2						

	Main Activity group code	Description of Main Activity group	Business Activity Code	Description of Business Activity	% of turnover of the company
1	М	Professional, Scientific and Technical	M5	Scientific research and development	69.57
2	С	Manufacturing	C6	Chemical and chemical products, pharmaceuticals, medicinal chemical and	30.43

# III. PARTICULARS OF HOLDING, SUBSIDIARY AND ASSOCIATE COMPANIES (INCLUDING JOINT VENTURES)

*No. of Companies for which information is to be given	5	Pre-fill All

S.No	Name of the company	CIN / FCRN	Holding/ Subsidiary/Associate/ Joint Venture	% of shares held
1	GVK DAVIX TECHNOLOGIES PR	U74110TG2005PTC045481	Holding	49.75
2	ARAGEN BIOSCIENCE INC		Subsidiary	100
3	ARAGEN LIFE SCIENCES B.V.		Subsidiary	100
4	INTOX PRIVATE LIMITED	U74999PN2000PTC015116	Subsidiary	56.82
5	ARAGEN FOUNDATION	U85300DL2021NPL391515	Subsidiary	100

IV. SHARE CAPITAL, DEBENTURES AND OTHER SECURITIES OF THE COMPANY

#### (i) \*SHARE CAPITAL

#### (a) Equity share capital

Particulars	Authorised capital	Issued capital	Subscribed capital	Paid up capital
Total number of equity shares	115,000,000	68,138,063	68,138,063	68,138,063
Total amount of equity shares (in Rupees)	1,150,000,000	681,380,630	681,380,630	681,380,630

Number of classes 1

Class of Shares Equity	Authoricad	icapitai	Subscribed capital	Paid up capital
Number of equity shares	115,000,000	68,138,063	68,138,063	68,138,063
Nominal value per share (in rupees)	10	10	10	10
Total amount of equity shares (in rupees)	1,150,000,000	681,380,630	681,380,630	681,380,630

#### (b) Preference share capital

Particulars	Authorised capital	Issued capital	Subscribed capital	Paid-up capital
Total number of preference shares	0	0	0	0
Total amount of preference shares (in rupees)	0	0	0	0

Number of classes 0

	Authoricad	Issued capital	Subscribed capital	Paid up capital
Number of preference shares				
Nominal value per share (in rupees)				
Total amount of preference shares (in rupees)				

#### (c) Unclassified share capital

Particulars	Authorised Capital
Total amount of unclassified shares	0

#### (d) Break-up of paid-up share capital

Class of shares	Number of shares			Total nominal amount	Total Paid-up amount	Total premium
Equity shares	Physical	DEMAT	Total			
At the beginning of the year	802,452	66,180,000	66982452	669,824,520	669,824,52	

Increase during the year	48,835	1,106,776	1155611	11,556,110	11,556,110	0
i. Pubic Issues	0	0	0	0	0	0
ii. Rights issue	0	0	0	0	0	0
iii. Bonus issue	0	0	0	0	0	0
iv. Private Placement/ Preferential allotment	0	0	0	0	0	0
v. ESOPs	48,835	1,106,776	1155611	11,556,110	11,556,110	
vi. Sweat equity shares allotted	0	0	0	0	0	0
vii. Conversion of Preference share	0	0	0	0	0	0
viii. Conversion of Debentures	0	0	0	0	0	0
ix. GDRs/ADRs	0	0	0	0	0	0
x. Others, specify						
Decrease during the year	0	0	0	0	0	0
i. Buy-back of shares	0	0	0	0	0	0
ii. Shares forfeited	0	0	0	0	0	0
iii. Reduction of share capital	0	0	0	0	0	0
iv. Others, specify						
At the end of the year	851,287	67,286,776	68138063	681,380,630	681,380,63	
Preference shares						
At the beginning of the year	0	0	0	0	0	
Increase during the year	0	0	0	0	0	0
i. Issues of shares	0	0	0	0	0	0
ii. Re-issue of forfeited shares	0	0	0	0	0	0
iii. Others, specify						
Decrease during the year	0	0	0	0	0	0
i. Redemption of shares	0	0	0	0	0	0

ii. Shares forfeited		0	0	0	0	0	0
iii. Reduction of share capit	tal	0	0	0	0	0	0
iv. Others, specify		1					
At the end of the year		0	0	0	0	0	
			Ŭ				
SIN of the equity shares o	of the company						
(ii) Details of stock spli	t/consolidation during the	e year (for ea	ch class of s	shares)	0		
Class of	f shares	(i)		(ii)		(ii	i)
Before split /	Number of shares						
Consolidation	Face value per share						
A 60 111 /	Number of shares						
After split / Consolidation	Face value per share						
Concomutation	1						
of the first return a	es/Debentures Trans t any time since the vided in a CD/Digital Medi	incorporati	ion of the			year (or i	
Separate sheet att	ached for details of transf	ers	• '	Yes 🔘	No		
Note: In case list of trans Media may be shown.	sfer exceeds 10, option for	submission a	as a separate	sheet attach	nment or sub	omission in	a CD/Digital
Date of the previous	Date of the previous annual general meeting 07/07/2021						
Date of registration of transfer (Date Month Year)							
Type of transfe	ег	1 - Equity, 2	2- Preferen	ce Shares,3	- Debentu	res, 4 - Sto	ock
Number of Shares/ Debentures/ Units Transferred  Amount per Share/ Debenture/Unit (in Rs.)							

Ledger Folio of Transferor					
Transferor's Name					
	Surname	middle name	first name		
Ledger Folio of Trans	sferee				
Transferee's Name					
	Surname	middle name	first name		
Date of registration of transfer (Date Month Year)					
Type of transfer 1 - Equ		Equity, 2- Preference Shares,3	- Debentures, 4 - Stock		
Number of Shares/ Debentures/ Units Transferred		Amount per Share/ Debenture/Unit (in Rs.)			
Ledger Folio of Trans	sferor	_			
Transferor's Name					
	Surname	middle name	first name		
Ledger Folio of Transferee					
Transferee's Name					
	Surname	middle name	first name		
(iv) *Debentures (Outstanding as at the end of financial year)					

Particulars	Number of units	Nominal value per unit	Total value
Non-convertible debentures	2,000	1000000	2,000,000,000
Partly convertible debentures	0	0	0
Fully convertible debentures	0	0	0

Particulars	Number of units	Nominal value per unit	Total value
Total			2,000,000,000

#### **Details of debentures**

Class of debentures	Outstanding as at the beginning of the year	_	Decrease during the year	Outstanding as at the end of the year
Non-convertible debentures	0	2,000,000,000	0	2,000,000,000
Partly convertible debentures	0	0	0	0
Fully convertible debentures	0	0	0	0

#### (v) Securities (other than shares and debentures)

Type of Securities	Number of Securities		Paid up Value of each Unit	Total Paid up Value
Total				

### V. \*Turnover and net worth of the company (as defined in the Companies Act, 2013)

(i) Turnover

12,359,680,000

0

(ii) Net worth of the Company

10,429,900,000

#### VI. (a) \*SHARE HOLDING PATTERN - Promoters

S. No.	Category	Equ	ity	Preference	
		Number of shares	Percentage	Number of shares	Percentage
1.	Individual/Hindu Undivided Family				
	(i) Indian	12,030,406	17.66	0	
	(ii) Non-resident Indian (NRI)	0	0	0	
	(iii) Foreign national (other than NRI)	0	0	0	
2.	Government				
	(i) Central Government	0	0	0	
	(ii) State Government	0	0	0	
	(iii) Government companies	0	0	0	

3.	Insurance companies	0	0	0	
4.	Banks	0	0	0	
5.	Financial institutions	0	0	0	
6.	Foreign institutional investors	0	0	0	
7.	Mutual funds	0	0	0	
8.	Venture capital	0	0	0	
9.	Body corporate (not mentioned above)	33,900,000	49.75	0	
10.	Others	0	0	0	
	Total	45,930,406	67.41	0	0

**Total number of shareholders (promoters)** 

3			

### (b) \*SHARE HOLDING PATTERN - Public/Other than promoters

S. No.	Category	Equi	ty	Preference		
		Number of shares	Percentage	Number of shares	Percentage	
1.	Individual/Hindu Undivided Family					
	(i) Indian	0	0	0		
	(ii) Non-resident Indian (NRI)	51,835	0.08	0		
	(iii) Foreign national (other than NRI)	0	0	0		
2.	Government					
	(i) Central Government	0	0	0		
	(ii) State Government	0	0	0		
	(iii) Government companies	0	0	0		
3.	Insurance companies	0	0	0		
4.	Banks	0	0	0		
5.	Financial institutions	0	0	0		
6.	Foreign institutional investors	0	0	0		
7.	Mutual funds	0	0	0		

8.	Venture capital	0	0	0	
9.	Body corporate (not mentioned above)	21,356,370	31.34	0	
10.	Others GVK Bio Employees Welfare	799,452	1.17	0	
	Total	22,207,657	32.59	0	0

<b>Total number of shareholders (other than promoters)</b>	6
Total number of shareholders (Promoters+Public/ Other than promoters)	9

### VII. \*NUMBER OF PROMOTERS, MEMBERS, DEBENTURE HOLDERS (Details, Promoters, Members (other than promoters), Debenture holders)

Details	At the beginning of the year	At the end of the year
Promoters	3	3
Members (other than promoters)	2	6
Debenture holders	0	5

#### VIII. DETAILS OF DIRECTORS AND KEY MANAGERIAL PERSONNEL

#### (A) \*Composition of Board of Directors

Category	Number of directors at the beginning of the year		Number of directors at the end of the year		Percentage of shares held by directors as at the end of year	
	Executive	Non-executive	Executive	Non-executive	Executive	Non-executive
A. Promoter	0	1	0	1	0	8.83
B. Non-Promoter	1	6	1	7	0	0
(i) Non-Independent	1	4	1	4	0	0
(ii) Independent	0	2	0	3	0	0
C. Nominee Directors representing	0	1	0	2	0	0
(i) Banks & FIs	0	0	0	0	0	0
(ii) Investing institutions	0	0	0	0	0	0
(iii) Government	0	0	0	0	0	0
(iv) Small share holders	0	0	0	0	0	0

(v) Others	0	1	0	2	0	0
Total	1	8	1	10	0	8.83

Number of Directors and Key managerial personnel (who is not director) as on the financial year end date | 11

11

#### (B) (i) \*Details of directors and Key managerial personnel as on the closure of financial year

Name	DIN/PAN	Designation	Number of equity share(s) held	Date of cessation (after closure of financial year : If any)
INDIRA KRISHNA RED	00005230	Director	0	01/06/2022
VENKATA SANJAYREI	00005282	Director	0	
DAVINDER SINGH BRA	00068502	Director	6,015,203	
GERHARD MAYR	02734832	Director	0	
MANMAHESH KANTIPI	05241166	Director	0	
KESHAV GUNUPATI V	06593325	Director	0	
SAHAJBIR SINGH BRA	07197320	Director	0	10/06/2022
ROBERT RICHARD RU	08404004	Director	0	
AJAY SRIVASTAVA	00049912	Director	0	
RAJAT SOOD	07914803	Director	0	
ADAM RICHARD DAW	09184061	Director	0	

#### (ii) Particulars of change in director(s) and Key managerial personnel during the year

7

Name	DIN/PAN	Designation at the beginning / during the financial year	Date of appointment/ change in designation/ cessation	Nature of change (Appointment/ Change in designation/ Cessation)
RAJAT SOOD	07914803	Additional director	19/05/2021	Appointment
AJAY SRIVASTAVA	00049912	Additional director	20/05/2021	Appointment
ADAM RICHARD DAWS	09184061	Additional director	31/05/2021	Appointment
RAJAT SOOD	07914803	Director	19/05/2021	Change in Designation
AJAY SRIVASTAVA	00049912	Director	07/07/2021	Change in Designation
ADAM RICHARD DAWS	09184061	Director	07/07/2021	Change in Designation
SANJIV DWARKANATH	01550413	Director	18/05/2021	Cessation

### IX. MEETINGS OF MEMBERS/CLASS OF MEMBERS/BOARD/COMMITTEES OF THE BOARD OF DIRECTORS

#### A. MEMBERS/CLASS /REQUISITIONED/NCLT/COURT CONVENED MEETINGS

Number of meetings held	3	
-------------------------	---	--

Type of meeting	Date of meeting			ance
		attend meeting	Number of members attended	% of total shareholding
Extra Ordinary General Mee	28/04/2021	5	4	84
Extra Ordinary General Mee	19/05/2021	8	6	82
Annual General Meeting	07/07/2021	8	8	100

#### **B. BOARD MEETINGS**

*Number of meetings held	5
--------------------------	---

S. No.	Date of meeting	Total Number of directors associated as on the date		Attendance
		of meeting	Number of directors attended	% of attendance
1	24/05/2021	10	10	100
2	26/07/2021	11	11	100
3	28/10/2021	11	11	100
4	28/01/2022	11	11	100
5	31/03/2022	11	11	100

#### C. COMMITTEE MEETINGS

Number of meetings held	7
Number of meetings held	7

S. No.	Type of meeting	Date of meeting	Total Number of Members as		Attendance
		Date of meeting	on the date of the meeting	Number of members attended	% of attendance
1	AUDIT COMM	24/05/2021	3	3	100
2	AUDIT COMM	26/07/2021	3	3	100
3	AUDIT COMM	28/10/2021	3	3	100
4	AUDIT COMM	28/01/2022	3	3	100

S. No.	Type of meeting	Date of meeting	Total Number of Members as		Attendance
			l	Number of members attended	% of attendance
5	NOMINATION	01/07/2021	4	4	100
6	NOMINATION	10/02/2022	4	4	100
7	CORPORATE	25/01/2022	4	4	100

#### D. \*ATTENDANCE OF DIRECTORS

		Board Meetings			Committee Meetings			Whether attended AGM
S. No.	Name of the director		Number of Meetings	% of attendance	Number of Meetings which director was	Number of Meetings	% of attendance	held on
		entitled to attend	attended	alleridance	entitled to attend	attended	alleridance	24/08/2022
								(Y/N/NA)
1	INDIRA KRISI	5	5	100	6	6	100	No
2	VENKATA SA	5	5	100	1	1	100	No
3	DAVINDER SI	5	5	100	3	3	100	No
4	GERHARD MA	5	5	100	1	1	100	No
5	MANMAHESH	5	5	100	0	0	0	No
6	KESHAV GUN	5	5	100	0	0	0	Yes
7	SAHAJBIR SII	5	5	100	0	0	0	No
8	ROBERT RIC	5	5	100	2	2	100	No
9	AJAY SRIVAS	5	5	100	4	4	100	No
10	RAJAT SOOD	5	5	100	7	7	100	No
11	ADAM RICHA	4	4	100	0	0	0	No

#### X. \*REMUNERATION OF DIRECTORS AND KEY MANAGERIAL PERSONNEL

	7	N I	:	ı
1		I٧	i	ı

Number of Managing Director, Whole-time Directors and/or Manager whose remuneration details to be entered

1		
---	--	--

S. No.	Name	Designation	Gross Salary	Commission	Stock Option/ Sweat equity	Others	Total Amount
1	MANMAHESH KAN	Director & CEO	54,835,707	0	382,720,728	252,222	437,808,657
	Total		54,835,707	0	382,720,728	252,222	437,808,657

S. No.	Name	Designation	Gross Salary	Commission	Stock Option/	Others	Total
		J			Sweat equity		Amount
1							0
	Total						
mber o	of other directors whose	remuneration det	ails to be entered		1	8	
6. No.	Name	Designation	Gross Salary	Commission	Stock Option/ Sweat equity	Others	Total Amount
1	DAVINDER SINGH	Director	0	0	0	302,222	302,222
2	VENKATA SANJAY	Director	0	0	0	252,222	252,222
3	INDIRA KRISHNA F	Director	0	0	0	403,333	403,333
4	KESHAV GUNUPA	Director	0	0	0	252,222	252,222
5	SAHAJBIR SINGH I	Director	0	0	0	259,070	259,070
6	GERHARD MAYR	Director	4,530,000	0	117,840,000	284,169	122,654,16
7	ROBERT RICHARD	Director	0	0	0	344,304	344,304
8	AJAY SRIVASTAVA	Director	0	0	0	353,333	353,333
	Total		4,530,000	0	117,840,000	2,450,875	124,820,87
pro	ether the company has visions of the Companio No, give reasons/observ	es Act, 2013 durin	es and disclosures in	n respect of applic	<sup>able</sup> <b>●</b> Yes	○ No	
	ILS OF PENALTIES / F			NY/DIRECTORS	/OFFICERS ☑ ▮	Nil	
						···	
		he court/		of the Act and	etails of penalty/	Details of appeal	
ame o		d Date o		sed / punished p	unishment	including present	status
ame o	f the concerned	d Date o		ın	unishment	including present	status

	-	Name of the cou concerned Authority	rt/ Date of Order	Name of the Act and section under which offence committed	Particulars of offence	Amount of compounding (in Rupees)
4RAC	SEN LIFE SC	RESERVE BAI	NK ( 02/03/2022	Foreign Exchange M	Delayed reporting	36,250
KIII. V	hether compl	ete list of sharel	nolders, debenture ho	olders has been enclose	ed as an attachment	
	<ul><li>Yes</li></ul>	s O No				
(IV. C	COMPLIANCE	OF SUB-SECTION	N (2) OF SECTION 92	2, IN CASE OF LISTED O	COMPANIES	
				are capital of Ten Crore rurtifying the annual return		over of Fifty Crore rupees or
Na	me	A	BHIMESWARA RAO			
Wh	ether associate	or fellow	<ul><li>Associa</li></ul>	te O Fellow		
Ce	ertificate of prac	ctice number	13380			
a) Th b) Un		expressly stated		ne closure of the financial ere in this Return, the Co		etly and adequately. with all the provisions of the
c) Th he ca securi d) Wh	e company has se of a first reti ties of the com nere the annua ds two hundred	s not, since the da urn since the date pany. I return discloses d, the excess con	e of the incorporation of the fact that the number	f the company, issued an er of members, (except in who under second provis	y invitation to the publ n case of a one persor	last return was submitted or lic to subscribe for any n company), of the company -section (68) of section 2 of
he Ac			Decl	aration		
he Ac		ne Board of Direc	tors of the company vio	de resolution no 4	date	ed 03/08/2022
	Authorised by th				ies Δct 2013 and the	rules made thereunder
am A	/IM/YYYY) to si	gn this form and		uirements of the Compan lental thereto have been o		
l am <i>l</i> (DD/M	MM/YYYY) to si pect of the subj Whatever is	gn this form and of this stated in this form	form and matters incided mand in the attachment	lental thereto have been onto	compiled with. I furthe t and complete and no	r declare that:

punishment for fraud, punishment for false statement and punishment for false evidence respectively.

To be digitally signed by

Director

MANMAHE Digitally signed by SH MANMAHE NAME (SH MANMAHE)

NAME (SH MANMAHE)

MANMAHE Digitally signed by MANMAHE SH MANMAHE)

MANMAHE Digitally signed by MANMAHE SAME (SH MANMAHE)

MANMAHE Digitally signed by MANMAHE SAME SH MANMAHE SH MANMAH SH

<ul><li>Company Secretary</li></ul>	1			
Company secretary	in practice			
Membership number	3865	Certifica	ate of practice number	
Attachments				List of attachments
1. List of shar	re holders, debenture	holders	Attach	List of share and Debenture holders as on
2. Approval le	etter for extension of	AGM;	Attach	MGT-8_Aragen Life Sciences-2021-22.pdf List of shares and Debentures transfers-Ar
3. Copy of Mo	GT-8;		Attach	List of shareholders-Scheme-Aragen Life Sexplanation letter-Aragen Life Sciences MQ
4. Optional A	ttachement(s), if any		Attach	
				Remove attachment
	Modify	Check Form	Prescrutir	Submit

This eForm has been taken on file maintained by the Registrar of Companies through electronic mode and on the basis of statement of correctness given by the company



#### **ARAGEN LIFE SCIENCES PRIVATE LIMITED**

#### List of Shareholders of the Company as on 31.03.2022

S. No.	DP ID	Client ID	Name of the Shareholders	No. of Shares	%	
1.	IN302084	10009740	GVK Davix Technologies Private Limited	33,900,000	49.75	
2.	IN305099	10008438	D S Brar	6,015,203	8.83	
3.	IN302084	10010673	Aparna Reddy Gunupati (as a Trustee of Reddy Investment Trust)	6,015,203	8.83	
4.		63	GVK Bio Employees Welfare Trust	799,452	1.17	
			Goldman Sachs Capital Holdings III Pte.			
5.	IN301524	30053402	Ltd.	5,159,708	7.57	
6.	IN301524	30053146	WSCPVIII Emp (Singapore) Pte. Ltd.	4,699,518	6.90	
7.	IN301524	30053138	WSCPVIII (Singapore) Pte. Ltd.	11,141,008	16.35	
			WSCPVIII Parallel Intermediary			
8.	IN301524	30053363	(Singapore) Pte. Ltd.	356,136	0.52	
9.		67	Tarun Khanna	51,835	0.08	
	Total No. of Shares 68,138,063					

For Aragen Life Spiences Private Limited



#### ARAGEN LIFE SCIENCES PRIVATE LIMITED

#### List of Debentureholders of the Company as on 31.03.2022

				No.of	
S.No.	DP ID	Client ID	Name of the Debentureholder	Debentures	%
1.	IN303270	10037180	Yes Bank Limited	1250	62.5
			Madhya Bharat Phosphate Private	39	
2.	IN302927	10368383	Limited		1.95
				183	
3.	IN302927	10365688	Kisan Phosphates Private Limited		9.15
			Shree Pushkar Chemicals And Fertilisers		
4.	IN302927	10348931	Limited	128	6.4
5.	IN301330	21716964	Tata Capital Financial Services Ltd	400	20
	Total No. of Debentures 2000				

For Aragen Life Sciences Private Limited



# Company Secretaries

B-41/A, Sai Sikhara, Ground Floor, Madhura Nagar, Hyderabad-38. Ph. No: 9291516984.

E-mail: bhimeshappana@gmail.com.

#### FORM NO. MGT-8

Pursuant to Section 92 (2) of the Companies Act, 2013 and Rule 11 (2) of Companies (Management and Administration) Rules, 2014

#### CERTIFICATE BY A COMPANY SECRETARY IN PRACTICE

I have examined the registers, records and books and papers of M/s. ARAGEN LIFE SCIENCES PRIVATE LIMITED (formerly known as GVK BIOSCIENCES PRIVATE LIMITED) having its registered office at Plot 28A, IDA Nacharam, Hyderabad-500076. TG. (hereafter referred to as the Company) as required to be maintained under the Companies Act, 2013 ('the Act') and the rules made there under for the Financial Year ended on 31<sup>st</sup> March, 2022. In my opinion and to the best of my information and according to the examinations carried out by me and explanations furnished to me by the company, its officers and agents, and I certify that:

- A. The Annual Return states the facts as at the close of the aforesaid Financial Year correctly and adequately.
- **B.** During the aforesaid Financial Year the Company has complied with provisions of the Act &Rules made there under in respect of:

S. No	Particulars	Remarks
1	Its status under the Act;	Complied with the provisions of the Act, as a Private Limited Company.
2	Maintenance of registers/ records & making entries there in within the time prescribed there for;	As confirmed to me, the entries in the registers were made within the prescribed time.
3	Filing of forms and returns as stated in the Annual Return, with the Registrar of Companies, Regional Director, Central Government, the Tribunal, Court or other authorities within/ beyond the prescribed time;	The Forms and Returns were filed with the Registrar of Companies are within the prescribed time/some forms beyond the prescribed time with necessary additional fee.
4	Calling/ convening/ holding meetings of Board of Directors or its committees, if any, and the meetings of the members of the	The meetings of Board of Directors and its Committees were held on the due dates as mentioned in the Annual Return in respect of which meetings proper notices were given
<b>5.</b>	company on due dates as stated in the annual return in respect of which meetings, proper notices	and the proceedings were properly recorded and signed the Minutes Book maintained for the purpose/registers maintained for the



## Company Secretaries

Company Secretaries
B-41/A, Sai Sikhara, Ground Floor,
Madhura Nagar, Hyderabad-38.
Ph. No: 9291516984.

E-mail: bhimeshappana@gmail.com.

	were given and the proceedings including the circular resolutions have been properly recorded in the Minute Book/registers maintained for the purpose and the same have been signed;	The Meetings of the Members of the Company were duly held on due dates as stated in the annual return in respect of which meetings, proper notices were given and the proceedings have been properly recorded in the Minutes Book/registers maintained for the purpose and the same have been signed.
5	Closure of Register of Members/ Security holders, as the case may be.	The Company has not closed the Register of Member/Security holders.
6	Advances/loans to its directors and/or persons or firms or companies referred in section 185 of the Act;	During the year, the Company has not provided any loans/advances to its directors and/or persons or firms or companies referred in section 185 of the Act;
7	Contracts/arrangements with related parties as specified in section 188 of the Act;	The Company Complied with the provisions of Section 188(1) of the Companies Act, 2013.
8	Issue or allotment or transfer or transmission or buy back of securities/ redemption of preference shares or debentures/ alteration or reduction of share capital/ conversion of shares/ securities and issue of security certificates in all instances;	There was no transmission or buy-back of securities/redemption of preference shares /debentures during the year. The Company has also not carried out any reduction of share capital/conversion of shares/securities during the year.  During the year, the Company has allotted equity shares to employees through the stock option schemes and there were transfers of shares. The Company issued 2000 (Two Thousand) listed, rated, secured, redeemable, nonconvertible debentures of the face value of Rs. 10,00,000/- (INR Ten Lakhs) each, aggregating up to Rs 200 Crores (INR Two Hundred Crores) (NCDs/Securities) in dematerialized form through Private Placement, and listed on stock exchange — BSE Limited.
9	Keeping in abeyance the rights to dividend, rights shares and bonus shares pending registration of transfer of shares in compliance with the provisions of the Act	There were no transactions necessitating the Company to keep in abeyance the rights to dividend, rights shares and bonus shares pending registration of transfer of shares.

2 | Page



### ABK & ASSUCIATES

Company Secretaries B-41/A, Sai Sikhara, Ground Floor, Madhura Nagar, Hyderabad-38. Ph. No: 9291516984.

E-mail: bhimeshappana@gmail.com.

10	Declaration/ payment of dividend; transfer of unpaid/ unclaimed dividend/other amounts as applicable to the Investor Education and Protection Fund in accordance with section 125 of the Act;	No Dividend was declared and paid during the FY 2021-22. However, a final dividend of Rs. 8.64/- per equity share has been declared and paid for the Financial Year 2021-22 in FY23.  The Company was not required to transfer any amount to the Investor Education and Protection Fund as there is no unpaid/ unclaimed dividend, matured deposits, matured debentures and the interest accrued thereon, in accordance with Section 125 of the Act.
11	Signing of audited financial statement as per the provisions of section 134 of the Act and report of directors is as per sub – sections (3), (4) and (5) thereof;	The Company has complied with the provisions of the Section 134 of the Act.
12	Constitution/ appointment/ reappointments/ retirement/ filling up casual vacancies/ disclosures of the Directors, Key Managerial Personnel and the remuneration paid to them;	During the year, one (1) Director resigned from the Company and three (3) were appointed as Additional Directors, who were subsequently regularized as Directors of the Company at the General Meetings held during the year. Due compliance is made in respect of the Constitution/disclosures/appointment of the Directors.  Being a Private Limited Company, provisions related to Key Managerial Personnel are not applicable to the Company.  Directors were paid remuneration as
12	Appaintment/	Provided in the Form MGT-7.
13	Appointment/ reappointment/ filling up casual vacancies of auditors as per the provisions of section 139 of the Act;	The Company has complied with the provisions of Section 139 of the Act, with respect to Appointment of Statutory Auditors of the Company.
14	Approvals required to be taken from the Central Government, Tribunal, Regional Director, Registrar, Court or such other authorities under the various provisions of the Act;	During the financial year the Company was not required to obtain any approvals from the Central Government, Tribunal, Regional Director, Registrar, Court or such other authorities under the various provisions of the Act except below:

Page

ABK & ASSOCIATES

B

**Company Secretaries** B-41/A, Sai Sikhara, Ground Floor,

Madhura Nagar, Hyderabad-38.

Ph. No: 9291516984.

E-mail: bhimeshappana@gmail.com.

		During the previous year, Excelra Knowledge Solutions Private Limited, GVK Davix Technologies Private Limited (GVK Davix), GVK Davix Research Private Limited and the Company and their respective shareholders have entered a Composite Scheme of Arrangement under Section 230 to 232 of the Companies Act, 2013 ("Scheme") which contemplates amalgamation of the residual GVK Davix post demerger of its informatics business excluding the investment in the Company, into the Company.
		During the year, All companies involved in the Scheme have filed Joint Petition with NCLT for approval to the Scheme.
		Post the year under review, the said Scheme was approved by the National Company Law Tribunal, Hyderabad Bench ("NCLT") on 30 <sup>th</sup> May 2022 and the Company has received the final order copy on 07 <sup>th</sup> June 2022. The certified copy of the said order has been filed with the Registrar of Companies, Hyderabad by the companies involved. The Company filed the certified copy of the Order on 01 <sup>st</sup> July 2022 with respect to Part IV of the Scheme concerning the amalgamation of GVK Davix with the Company, and the amalgamation has become operative from that date.
15	Acceptance/renewal/repayment of deposits;	During the year, the Company did not accept any deposits covered under the Chapter V of the Companies Act, 2013. However, pursuant to the Composite Scheme of Arrangement, the Unsecured loans of GVK Davix Technologies Private Limited (transferee Company) availed deposits from its shareholders amounting to Rs. 49.82 million have been transferred to the Company and the Company has repaid entire loan/deposit amount post the year under review.
16	Borrowings from its directors, members, public financial institutions, banks and others and	The Company has made borrowings from the Banks/financial institutions and complied with the provisions with the Act.

4 | Page



### ADN & ASSUCIATES

Company Secretaries
B-41/A, Sai Sikhara, Ground Floor, Madhura Nagar, Hyderabad-38. Ph. No: 9291516984.

E-mail: bhimeshappana@gmail.com.

	creation/ modification/ satisfaction of charges in that respect, wherever applicable;	In relation to Non-Convertible Debentures issued and allotted during the year, the Company created a charge in favour of Debenture trustee and filed necessary forms with Registrar of Companies.  The Company has not made any borrowings from its directors, members, public financial institutions and others.
17	Loans and investments or guarantees given or providing of securities to other bodies corporate or persons falling under the provisions of section 186 of the Act;	The Company has not given any loans, guarantees or provided securities or acquired securities of any other body corporate exceeding the limits specified in Section 186(2) of the Companies Act.
		During the year, the Company acquired 56.82% shares of 'Intox Private Limited' in December 2021 with approval of board of directors of the Company.
		'Aragen Foundation' a Section-8 Company with charitable objects was incorporated as a wholly-owned subsidiary of the Company during the year.
18	Alteration of the provisions of the Memorandum and/ or Articles of	During the year under review.
	Association of the Company;	The Company has altered the provisions of Articles of Association during the year and no alterations made to Memorandum of Association.

For ABR & ASSOCIATES **Company Secretaries** 

Place: Hyderabad

Date: 26.09.2022

(A. BHIMESWARA RAO)

A. Bhimisways

Proprietor

M. No. 35521; C.P No.13380.

ICSI UDIN: A035521D001044716



#### ARAGEN LIFE SCIENCES PRIVATE LIMITED

#### Equity Share Transfers during 01.04.2021 to 31.03.2022

S. No	DP & Client ID/Folio No. of Transferor		DP & Client ID of Transferee	Name of the Transferee	No.of shares transferred	Considerat ion per equity share	Date of transfer (Date of Board of Directors approval)
1.	17	Ramesh Gambhir	63	GVK Bio Employees Welfare Trust	17566	INR 877.46	18/05/2021
2.	64	Manmahesh Kantipudi	63	GVK Bio Employees Welfare Trust	506800	INR 877.46	18/05/2021
3.	72	Sudhir Kumar Singh	63	GVK Bio Employees Welfare Trust	107037	INR 877.46	18/05/2021
4.	73	Suresh Anubolu	63	GVK Bio Employees Welfare Trust	47718	INR 877.46	18/05/2021
5.	74	Krishna S Ethiraj	63	GVK Bio Employees Welfare Trust	23410	INR 877.46	18/05/2021
6.	75	Somesh Sharma	63	GVK Bio Employees Welfare Trust	33460	INR 877.46	18/05/2021
7.	76	Amit Kumar Rustagi	63	GVK Bio Employees Welfare Trust	21535	INR 877.46	18/05/2021
8.	77	Sreehari Babu Putchakayala	63	GVK Bio Employees Welfare Trust	19106	INR 877.46	18/05/2021
9.	78	KMV Narayana Rao	63	GVK Bio Employees Welfare Trust	12743	INR 877.46	18/05/2021

**Registered & Corporate Office** 

Aragen Life Sciences Pvt. Ltd. (Formerly known as GVK Biosciences Pvt. Ltd.) 28 A, IDA Nacharam, Hyderabad 500 076, India T: +91 40 6692 9999 F: +91 40 6692 9900 W: aragen.com CIN: U74999TG2000PTC035826





10.	79	Muralidharan Kaliyaperumal	63	GVK Bio Employees Welfare Trust	11430	INR 877.46	18/05/2021
11.	80	Ramakrishna Kasturi	63	GVK Bio Employees Welfare Trust	14397	INR 877.46	18/05/2021
12.	81	Rongali Bangaru Babu	63	GVK Bio Employees Welfare Trust	8712	INR 877.46	18/05/2021
13.	82	Timmanna Upadhya	63	GVK Bio Employees Welfare Trust	10554	INR 877.46	18/05/2021
14.	83	Lakshman E Rajagopalan	63	GVK Bio Employees Welfare Trust	24564	INR 877.46	18/05/2021
15.	IN300126 11259035	Destiny Investments Limited	85 (IN301524 30053146)	Goldman Sachs Asia Strategic Pte. Ltd.	2,714,419	INR 877.46	19/05/2021
16.	IN300126 11259035	Destiny Investments Limited	85 (IN301524 30053146)	WSCPVIII Emp (Singapore) Pte. Ltd.	2,472,323	INR 877.46	19/05/2021
17.	IN300126 11259035	Destiny Investments Limited	86 (IN301524 30053138)	WSCPVIII (Singapore) Pte. Ltd.	5,861,062	INR 877.46	19/05/2021
18.	IN300126 11259035	Destiny Investments Limited	87 (IN301524 30053120)	WSCPVIII Parallel (Singapore) Pte. Ltd.	187,356	INR 877.46	19/05/2021
19.	IN302084 10010673) Aparna Reddy Gunupati  (as a Trustee of Reddy Investment Trust)		84 (IN301524 30044045)	Goldman Sachs Asia Strategic Pte. Ltd.	1,088,945	INR 877.46	19/05/2021



(Formerly known as GVK Biosciences Pvt. Ltd.) 28 A, IDA Nacharam, Hyderabad 500 076, India T: +91 40 6692 9999 F: +91 40 6692 9900 W: aragen.com CIN: U74999TG2000PTC035826







		·					
20.	IN302084 10010673)	Aparna Reddy Gunupati (as a Trustee of Reddy Investment Trust)	85 (IN301524 30053146)	WSCPVIII Emp (Singapore) Pte. Ltd.	991,823	INR 877.46	19/05/2021
21.	IN302084 10010673)	Aparna Reddy Gunupati (as a Trustee of Reddy Investment Trust)	86 (IN301524 30053138)	WSCPVIII (Singapore) Pte. Ltd.	2,351,286	INR 877.46	19/05/2021
22.	IN302084 10010673)	Aparna Reddy Gunupati (as a Trustee of Reddy Investment Trust)	87 (IN301524 30053120)	WSCPVIII Parallel (Singapore) Pte. Ltd.	75,163	INR 877.46	19/05/2021
23.	(IN305099 10008438)	Davinder Singh Brar	84 (IN301524 30044045)	Goldman Sachs Asia Strategic Pte. Ltd.	1,088,946	INR 877.46	19/05/2021
24.	(IN305099 10008438)	Davinder Singh Brar	85 (IN301524 30053146)	WSCPVIII Emp (Singapore) Pte. Ltd.	991,824	INR 877.46	19/05/2021
25.	(IN305099 10008438)	Davinder Singh Brar	86 (IN301524 30053138)	WSCPVIII (Singapore) Pte. Ltd.	2,351,287	INR 877.46	19/05/2021
26.	(IN305099 10008438)	Davinder Singh Brar	87 (IN301524 30053120)	WSCPVIII Parallel (Singapore) Pte. Ltd.	75,160	INR 877.46	19/05/2021
27.	63	GVK BIO Employees' Welfare Trust	84 (IN301524 30044045)	Goldman Sachs Asia Strategic Pte. Ltd.	2,08,267	INR 877.46	19/05/2021
28.	63	GVK BIO Employees' Welfare Trust	85 (IN301524 30053146)	WSCPVIII Emp (Singapore) Pte. Ltd.	1,89,692	INR 877.46	19/05/2021

Registered & Corporate Office Aragen Life Sciences Pvt. Ltd.

(Formerly known as GVK Biosciences Pvt. Ltd.) 28 A, IDA Nacharam, Hyderabad 500 076, India T: +91 40 6692 9999 F: +91 40 6692 9900 W: aragen.com CIN: U74999TG2000PTC035826







r						T	I
29.	63	GVK BIO Employees' Welfare Trust	86 (IN301524 30053138)	WSCPVIII (Singapore) Pte. Ltd.	4,49,697	INR 877.46	19/05/2021
30.	63	GVK BIO Employees' Welfare Trust	87 (IN301524 30053120)	WSCPVIII Parallel (Singapore) Pte. Ltd.	14376	INR 877.46	19/05/2021
31.	67	Tarun Khanna	84 (IN301524 30044045)	Goldman Sachs Asia Strategic Pte. Ltd.	18785	INR 877.46	12/08/2021
32.	67	Tarun Khanna	85 (IN301524 30053146)	WSCPVIII Emp (Singapore) Pte. Ltd.	17110	INR 877.46	12/08/2021
33.	67	Tarun Khanna	86 (IN301524 30053138)	WSCPVIII (Singapore) Pte. Ltd.	40562	INR 877.46	12/08/2021
34.	67	Tarun Khanna	87 (IN301524 30053120)	WSCPVIII Parallel (Singapore) Pte. Ltd.	1296	INR 877.46	12/08/2021
35.	88	Gerhard Mayr	84 (IN301524 30044045)	Goldman Sachs Asia Strategic Pte. Ltd.	33824	INR 877.46	12/08/2021
36.	88	Gerhard Mayr	85 (IN301524 30053146)	WSCPVIII Emp (Singapore) Pte. Ltd.	30807	INR 877.46	12/08/2021
37.	88	Gerhard Mayr	86 (IN301524 30053138)	WSCPVIII (Singapore) Pte. Ltd.	73034	INR 877.46	12/08/2021
38.	88	Gerhard Mayr	87 (IN301524 30053120)	WSCPVIII Parallel (Singapore) Pte. Ltd.	2335	INR 877.46	12/08/2021

Registered & Corporate Office Aragen Life Sciences Pvt. Ltd.

(Formerly known as GVK Biosciences Pvt. Ltd.) 28 A, IDA Nacharam, Hyderabad 500 076, India T: +91 40 6692 9999 F: +91 40 6692 9900 W: aragen.com CIN: U74999TG2000PTC035826







			0.4	<u> </u>			
39.	89	Srinivas Reddy Mamidi	84 (IN301524 30044045)	Goldman Sachs Asia Strategic Pte. Ltd.	3775	INR 877.46	27/08/2021
40.	89	Srinivas Reddy Mamidi	85 (IN301524 30053146)	WSCPVIII Emp (Singapore) Pte. Ltd.	3438	INR 877.46	27/08/2021
41.	89	Srinivas Reddy Mamidi	86 (IN301524 30053138)	WSCPVIII (Singapore) Pte. Ltd.	8151	INR 877.46	27/08/2021
42.	89	Srinivas Reddy Mamidi	87 (IN301524 30053120)	WSCPVIII Parallel (Singapore) Pte. Ltd.	261	INR 877.46	27/08/2021
43.	90	Brian Michael Shaughnessy	84 (IN301524 30044045)	Goldman Sachs Asia Strategic Pte. Ltd.	2,747	INR 877.46	06/10/2021
44.	90	Brian Michael Shaughnessy	85 (IN301524 30053146)	WSCPVIII Emp (Singapore) Pte. Ltd.	2,501	INR 877.46	06/10/2021
45.	90	Brian Michael Shaughnessy	86 (IN301524 30053138)	WSCPVIII (Singapore) Pte. Ltd.	5,929	INR 877.46	06/10/2021
46.	90	Brian Michael Shaughnessy	87 (IN301524 30053120)	WSCPVIII Parallel (Singapore) Pte. Ltd.	189	INR 877.46	06/10/2021
47.	(IN301524 30044045)	Goldman Sachs Asia Strategic Pte. Ltd.	(IN301524 30053402)	Goldman Sachs Capital Holdings III Pte. Ltd	5159708	INR 877.46	08/11/2021







48.	(IN301524 30053120)	WSCPVIII Parallel (Singapore) Pte. Ltd.	(IN301524 30053363)	WSCPVIII Parallel Intermediary (Singapore) Pte. Ltd.	356136	INR 877.46	08/11/2021
-----	------------------------	--	------------------------	--	--------	------------	------------

For Aragen Life Spiences Private Limited



#### ARAGEN LIFE SCIENCES PRIVATE LIMITED

#### Debenture Transfers (through demat mode) during FY 2022

	DP & Client		DP &			
	ID/Folio		Client ID		No. of	Period of
	No. of	Name of the	of	Name of the	Debentures	Transfer
S. No	Transferor	Transferor	Transferee	Transferee	transferred	
				Tata Capital		Between
				Financial		04.03.2022
	IN302927	JM Financial	IN301330	Services Ltd		to
1	10338169	Products Ltd	21716964		400	11.03.2022
				Shree Pushkar		Between
				Chemicals and		04.03.2022
	IN302927	JM Financial	IN302927	Fertilisers		to
2	10338169	Products Ltd	10348931	Limited	65	11.03.2022
						Between
				Kisan		04.03.2022
	IN302927	JM Financial	IN302927	Phosphates	183	to
3	10338169	Products Ltd	10365688	Private Limited		11.03.2022
						Between
				Madhya Bharat		04.03.2022
	IN302927	JM Financial	IN302927	Phosphate		to
4	10338169	Products Ltd	10368383	Private Limited	102	11.03.2022
		Madhya				Between
		Bharat		Shree Pushkar		25.03.2022
-		Phosphate		Chemicals and		to
	IN302927	Private	IN302927	Fertilisers		31.03.2022
5	10368383	Limited	10348931	Limited	63	

For Aragen Life Sciences Private Limited



#### ARAGEN LIFE SCIENCES PRIVATE LIMITED

#### List of Shareholders of the Company as on 31.03.2022

#### (Prior to the Composite Scheme of Arrangement)

				No. of	
S. No.	DP ID	Client ID	Name of the Shareholders	Shares	%
			GVK Davix Technologies Private		
1.	IN302084	10009740	Limited*	33,900,000	49.75
2.	IN305099	10008438	D S Brar	6,015,203	8.83
			Aparna Reddy Gunupati (as a Trustee of	6,015,203	
3.	IN302084	10010673	Reddy Investment Trust)		8.83
4.		63	GVK Bio Employees Welfare Trust	799,452	1.17
			Goldman Sachs Capital Holdings III Pte.		
5.	IN301524	30053402	Ltd.	5,159,708	7.57
6.	IN301524	30053146	WSCPVIII Emp (Singapore) Pte. I.td.	4,699,518	6.90
7.	IN301524	30053138	WSCPVIII (Singapore) Pte. Ltd.	11,141,008	16.35
			WSCPVIII Parallel Intermediary		
8.	IN301524	30053363	(Singapore) Pte. Ltd.	356,136	0.52
9.		67	Tarun Khanna	51,835	0.08
		Total	No. of Shares	68,138,063	100.00

\* Pursuant to the composite scheme of arrangement between Excelra Knowledge Solutions Private Limited, GVK Davix Technologies Private Limited ("GVK Davix Tech"), GVK Davix Research Private Limited and our Company, approved by the National Company Law Tribunal, Hyderabad Bench pursuant to an order dated May 30, 2022 and Effective from 1st July 2022 (i.e. date of filing of NCLT order with ROC) ("Composite Scheme of Arrangement"), amongst other things, 33,900,000 Equity Shares that were previously held by GVK Davix Tech in the Company were automatically cancelled upon 33,900,000 Equity Shares being issued and allotted by our Company to the shareholders of GVK Davix Tech on 7th July 2022, in proportion to the number of Equity Shares held by them in GVK Davix Tech. Further, pursuant to the Composite Scheme of Arrangement, GVK Davix Tech amalgamated with the Company and ceased to be a shareholder of the Company and no longer exists as on the date.

For Aragen Life Sciences Private Limited



#### List of Shareholders of the Company as on 21st October 2022

#### (Post effectuation of the Composite Scheme of Arrangement)

S. No.	DP ID	Client ID	Name of the Shareholders	No. of shares	%
1	IN305099	10008438	DS Brar#	16554971	24.30
			Aparna Reddy Gunupati		
2	IN302084	10010673	(as a Trustee of Reddy Investment Trust)	22056824	32.37
3		63	GVK Bio Employees Welfare Trust	799452	1.17
4	IN301524	30053402	Goldman Sachs Capital Holdings III Pte. Ltd.	5159708	7.57
5	IN301524	30053146	WSCPVIII Emp (Singapore) Pte. Ltd.	4699518	6.90
6	IN301524	30053138	WSCPVIII (Singapore) Pte. Ltd.	11141008	16.35
			WSCPVIII Parallel Intermediary (Singapore)		
7	IN301524	30053363	Pte. Ltd.	356136	0.52
8	es sud	67	Tarun Khanna	51835	0.08
9	IN301774	10005267	Madhubani Investments Private Limited	6410232	9.41
		95	Aparna Reddy Gunupati		
10			(as a Trustee of Reddy Family Trust)	908379	1.33
	7.		Total	68138063	100.00

#Including transfer of 161111 equity shares from Mr. Anandbir Singh Brar on 17th August 2022.

For Aragen Life Sciences Private Limiteo



#### TO WHOM SO EVER IT MAY CONCERN

Sub: Form MGT-7 Annual Return for FY22 of the Company.

This is to inform that, during the year, the Company allotted 1155611 equity shares under ESOP schemes of the Company and subsequently out of total allotted shares 1103776 shares were transferred (i.e. except 51835 shares) to other shareholders of the Company and these transferred shares got dematerialized during the year.

With respect to the Breakup of paid-up share capital section of form MGT-7: Out of opening balance of physical shares i.e., 802452 equity shares, 3000 shares were transferred to other shareholders and these transferred shares got dematerialized during the year and there is no specific column to show the details of shares which were dematerialized during the year in the form and we tried to show these 3000 dematerialized shares in others column of increased and decreased share capital line items but due to technical issue these details were not captured in the respective columns. So, in order to match with the closing balance of physical and demat shares, we have shown in physical mode 48835 shares instead of 51835 shares by reducing 3000 transferred shares and in demat mode 1106776 instead of 1103776 with addition of 3000 transferred shares in increase of paid-up share capital column under the ESOP item.

Please consider the above and take on record.

Thanking you,

For Aragen Life Sciences Private Limited

KASTURI Digitally signed by KASTURI RAMAKRISHNA Date: 2022.10.22 A 12:12:53 +05'30'

Ramakrishna Kasturi Company Secretary Date:22-10-2022